Physician profile
Dane Thurston
NPI 1225255235
$1,228.81
in general payments reported to CMS, 2019-2025
15 companies · $636 in 2025
The $636 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2024: $375 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.53 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $268.63 | 2024-2025 | Ingrezza |
| Abbvie INC. | $255.56 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $252.06 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $100.70 | 2024-2025 | Auvelity |
| Braeburn INC. | $87.73 | 2025 | Brixadi |
| Alkermes, INC. | $38.82 | 2025 | Aristada, Lybalvi |
| Lundbeck LLC | $38.13 | 2024 | Rexulti |
| Genentech USA, INC. | $37.41 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.15 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $35.16 | 2024-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $18.88 | 2025 | Rexulti |
| Indivior INC. | $18.06 | 2024 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $14.21 | 2025 | Cobenfy |
| Lilly USA, LLC | $13.77 | 2021 | |
| Novo Nordisk INC | $13.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dane Thurston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.